# AXIS 2: AX200 for the Treatment of Ischemic Stroke

> **NCT00927836** · PHASE2 · COMPLETED · sponsor: **Sygnis Bioscience GmbH & Co KG** · enrollment: 328 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **BIOLOGICAL:** Filgrastim
- **DRUG:** Sodium chloride solution

## Key facts

- **NCT ID:** NCT00927836
- **Lead sponsor:** Sygnis Bioscience GmbH & Co KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2011-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00927836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00927836, "AXIS 2: AX200 for the Treatment of Ischemic Stroke". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00927836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*